John Lu , PhD, MPH, is the President and CEO of HebeCell Corporation. focusing on the development of PSC-NK cells for the treatment of human diseases including cancer, autoimmune and viral infection diseases. Before establishing HebeCell, he was the Senior Director of R&D at Advanced Cell technology/Ocata Therapeutics for 11 years. John Has more than 30 years of expereince in stem cell and regenerative medicine as well as >10 year experiences of cancer research. In an anylysis of global stem cell patent landscape by Nature Biotechnology in 2014, John's patent application and citation ranked number 7 and 5 , respectively. Under John's leadership, HebeCell's properitary ProtoNK cell HC101 has recently been approved by US FDA for phase 1/1b clinical trial for refractory/recurrent Ewing sarcoma patients, which will start patient recrutment soon.